Archive - February 2022
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Incyte Provides Update on Parsaclisib and MCLA-145
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
WHO Warns Against Teleworking Dangers Amid COVID-19 Pandemic
CDC Says ‘We Have The Tools’ To Fight COVID’s Omicron Variant
New Omicron subvariant appears more transmissible but no more severe than original Omicron strain